Brachytherapy, a form of radiation therapy where radioactive seeds – or isotopes – are placed near or inside the tumor to emit radiation, is one of the most intriguing both in the medical and investor community.
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
Threshold Pharmaceuticals Selectively Targets Tumor Cells in Cancer Therapeutics
Threshold Pharmaceuticals takes advantage of the differences in metabolic activity between cancerous and normal, healthy biological tissue.
Provectus Pharmaceuticals Uses Old Drug To Actualize Novel Therapeutics for Cancer and Skin Disorders
Provectus Pharmaceuticals develops a powerful drug pipeline with minimal side effects, including a cancer drug that targets cancer tissue, as well as…
ADVENTRX Completes Acquisition of SynthRx
ADVENTRX and SynthRx, a private biotechnology company, completed a definitive merger on April 8, 2011.
Del Mar Pharmaceuticals Is Fighting Cancer One Molecule At A Time
Del Mar Pharmaceuticals was recently added to the roster of presenting companies at OneMedForum NY 2011.
Killing Canine Cancer:Functional Nutriments Applies Ground-Breaking Therapy To Human Patients (Video)
Cancer, a word that strikes a chord of fear in many, is a fighting word. At $47.7bn, cancer is one of the largest, fastest growing markets in the pharmaceutical industry, and while it is a match we have yet to win, researchers and scientists have on their boxing gloves and are staying in the fight.
Oncology Panel Selected in OneMedForum SF 2011
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
